AKTX
Akari Therapeutics Plc
Next earnings Aug 11, 2026 · consensus $-1.42 EPS
$10.73
▲ +12.71%$10.73▼ -76.88%
over 1Y
L $3.06EODHDH $46.80
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+12.7%
1W-4.5%
1M-32.6%
3M+112.9%
YTD-7.5%
1Y-76.9%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Conservative balance sheet (liabilities/equity 0.69x).
Return on equity -61.1% · latest
Akari Therapeutics Plc shows limited reported revenue, and -61.1% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$17.2M | -$23.1M | -$16.8M | -$21.6M | -$17.3M |
| Net income | -$17.4M | -$17.7M | -$10.0M | -$19.8M | -$17.3M |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$983B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-0.0%
FCF yield-0.0%
Quality & risk
ROIC (est.)-48.2%
Free cash flow-$10.6M
Total debt—
Net cash$0.00
Piotroski F-Score3/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+58.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-05-18). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-232026-06-26open ↗S-1/AFiling2026-06-26open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗SCHEDULE 13GFiling2026-06-08open ↗DEF 14APeriod ending 2026-06-042026-06-04open ↗DFiling2026-06-03open ↗PRE 14APeriod ending 2026-05-222026-05-22open ↗8-KPeriod ending 2026-05-202026-05-22open ↗RWFiling2026-05-21open ↗10-QPeriod ending 2026-03-312026-05-19open ↗NT 10-QPeriod ending 2026-03-312026-05-18open ↗
Frequently asked
- Is Akari Therapeutics Plc (AKTX) a buy?
- AKTX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.69x).
- What is Akari Therapeutics Plc's quality score?
- AKTX scores 53.71794871794872/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001541157, latest 10-Q filed 2026-05-19) · EODHD · as of 6/23/2026, 12:42:35 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.